Join Growin Stock Community!

Inhibikase therapeutics, inc.IKT.US Overview

US StockHealthcare
(No presentation for IKT)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

IKT AI Insights

IKT Overall Performance

IKT AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

IKT Recent Performance

-3.66%

Inhibikase therapeutics, inc.

0.05%

Avg of Sector

-0.31%

S&P500

IKT PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

IKT Key Information

IKT Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

IKT Profile

Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.

Price of IKT

IKT FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

IKT Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.67
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
1000000.00
PB Ratio
3.40
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-100.00%
Profit Growth (YoY)
-100.00%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.67
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
1000000.00
PB Ratio
3.40
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-100.00%
Profit Growth (YoY)
-100.00%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%

  • When is IKT's latest earnings report released?

    The most recent financial report for Inhibikase therapeutics, inc. (IKT) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating IKT's short-term business performance and financial health. For the latest updates on IKT's earnings releases, visit this page regularly.

  • How much cash does IKT have?

    At the end of the period, Inhibikase therapeutics, inc. (IKT) held Total Cash and Cash Equivalents of 38.27M, accounting for 0.48 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is IKT's EPS continuing to grow?

    According to the past four quarterly reports, Inhibikase therapeutics, inc. (IKT)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.13. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of IKT?

    Inhibikase therapeutics, inc. (IKT)'s Free Cash Flow (FCF) for the period is -10.59M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 117.02% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.